Altre lingue Eurocine Vaccines AB

Azioni

EUCI

SE0015382155

Prezzo di chiusura NORDIC GROWTH MARKET Altri mercati azionari 00:00:00 18/06/2024			Variaz. 5gg	Var. 1 gen.
0,0348 ^SEK	+10,13%		+8,75%	-24,35%

30/05	Eurocine Vaccines AB (publ) riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 31 marzo 2024	CI
28/02	Eurocine Vaccines AB (publ) riporta i risultati degli utili per il secondo trimestre e i sei mesi conclusi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Eurocine Vaccines AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	30/05
Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	28/02
Certain Shares of Eurocine Vaccines AB are subject to a Lock-Up Agreement Ending on 15-FEB-2024.	15/02
Correction - Eurocine Vaccines discloses interim report for July - September 2023	28/11
Eurocine Vaccines AB Reports Earnings Results for the First Quarter Ended September 30, 2023	28/11
Eurocine Vaccines discloses interim report for Juli - September 2023	28/11
Eurocine Vaccines AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2023	30/08/23
Eurocine Vaccines AB Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023	30/08/23
Eurocine Vaccines discloses interim report for July 2022 - March 2023	24/05/23
Eurocine Vaccines AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	24/05/23
Eurocine Vaccines Wins SEK300,000 Grant from Merck KGaA	04/05/23
Certain Shares of Eurocine Vaccines AB are subject to a Lock-Up Agreement Ending on 17-APR-2023.	17/04/23
Eurocine Vaccines discloses half-year report for July - December 2022	28/02/23
Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	28/02/23
Eurocine Vaccines to Develop Chlamydia Vaccine Candidate Using mRNA	18/01/23
Eurocine Vaccines decides to develop mRNA-based vaccine candidate against chlamydia	17/01/23
Eurocine Vaccines AB Decides to Develop mRNA-Based Vaccine Candidate Against Chlamydia	17/01/23
Outstanding results for Eurocine Vaccines' mRNA based HSV-2 candidate	21/12/22
Eurocine Vaccines : Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate	20/12/22
Eurocine Vaccines AB Reports Earnings Results for the First Quarter Ended September 30, 2022	29/11/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Eurocine Vaccines AB

Azioni

EUCI

SE0015382155

Altre lingue

Filtri